EUVIMEDEUVIMED entdecken
Open Access

SGLT2 Inhibitor–Associated Ketoacidosis vs Type 1 Diabetes–Associated Ketoacidosis

Mahesh M Umapathysivam, Bethany Morgan, Joshua M Inglis, Emily Meyer, Danny Liew, Venkatesan Thiruvenkatarajan, David Jesudason

JAMA Network Open · 18.03.2024 · 7 (3) · e242744

DOI: 10.1001/jamanetworkopen.2024.2744 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 18.03.2024. Verfasst von Mahesh M Umapathysivam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Southern Adelaide Diabetes and Endocrine Services, Flinders Medical Centre, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 1, Diabetic Ketoacidosis, Ketosis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 4 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This cohort study examines the natural history and response to treatment of sodium glucose cotransporter 2 (SGLT2) inhibitor–associated ketoacidosis compared with that of type 1 diabetes–associated ketoacidosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 1Diabetic KetoacidosisKetosisHumans

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Southern Adelaide Diabetes and Endocrine Services, Flinders Medical Centre, Adelaide, South Australia, Australia.
  • Endocrine Department, Queen Elizabeth Hospital, Woodville, South Australia, Australia.
  • Endocrine Department, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
  • Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, South Australia, Australia.
  • Anaesthetic Department, Queen Elizabeth Hospital, Woodville, South Australia, Australia.

Zitieren

APA

Umapathysivam, M. M., Morgan, B., Inglis, J. M., Meyer, E., Liew, D., Thiruvenkatarajan, V., & Jesudason, D. (2024). SGLT2 Inhibitor–Associated Ketoacidosis vs Type 1 Diabetes–Associated Ketoacidosis. JAMA Network Open, 7(3), e242744. https://doi.org/10.1001/jamanetworkopen.2024.2744

Vancouver

Umapathysivam MM, Morgan B, Inglis JM, Meyer E, Liew D, Thiruvenkatarajan V, et al. SGLT2 Inhibitor–Associated Ketoacidosis vs Type 1 Diabetes–Associated Ketoacidosis. JAMA Network Open. 2024;7(3):e242744. doi:10.1001/jamanetworkopen.2024.2744

BibTeX
@article{Umapathysivam2024,
  author = {Umapathysivam, Mahesh M and Morgan, Bethany and Inglis, Joshua M and Meyer, Emily and Liew, Danny and Thiruvenkatarajan, Venkatesan and Jesudason, David},
  title = {SGLT2 Inhibitor–Associated Ketoacidosis vs Type 1 Diabetes–Associated Ketoacidosis},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {3},
  pages = {e242744},
  doi = {10.1001/jamanetworkopen.2024.2744}
}
Kostenlos starten →